New clinical trial will evaluate an additional injection (booster) with Diamyd®
A new investigator-initiated clinical trial, DIAGNODE-B, will start this spring. The trial will evaluate the safety, impact on the immune system and the clinical efficacy of an additional injection with the antigen-specific immunotherapy Diamyd[®]. The trial has been approved by the Swedish Medical Products Agency and the Ethical Review Authority and will be offered to approximately 6 patients from the previous trials DIAGNODE-1 and DIAGNODE-2.The patients who will be included in DIAGNODE-B have previously been treated with either three or four intralymphatic injections of Diamyd[®]. All